Table 3 Management of myocardial infarction and of organ dysfunction on the day of the myocardial infarction according to occurrence of composite outcome components
Variable | Total (n = 96) | Severe ischemic eventa | Major bleeding eventb | Death | |||
|---|---|---|---|---|---|---|---|
Yes (n = 17) | No (n = 79) | Yes (n = 26) | No (n = 70) | Yes (n = 26) | No (n = 70) | ||
Myocardial infarction management | |||||||
Antiplatelet therapy | 95 (99) | 17 (100) | 78 (99) | 25 (96) | 70 (100) | 26 (100) | 69 (99) |
Dual antiplatelet therapy | 61 (64) | 10 (59) | 51 (65) | 11 (42) * | 50 (71) | 16 (61) | 45 (64) |
Therapeutic anticoagulation (MD = 1) | 68 (71) | 11 (65) | 57 (72) | 18 (69) | 50 (71) | 18 (69) | 50 (71) |
Early mechanical reperfusion therapyc, d | 47 (49) | 9 (53) | 38 (48) | 12 (46) | 35 (50) | 13 (50) | 34 (49) |
Organ dysfunction management | |||||||
Catecholamines | 48 (51) | 10 (59) | 38 (48) | 11 (42) | 37 (53) | 21 (81) * | 27 (39) |
Invasive mechanical ventilation | 56 (58) | 14 (82) | 42 (53) | 17 (65) | 39 (56) | 23 (88) * | 33 (47) |
Renal replacement therapy | 9 (9) | 3 (18) | 6 (8) | 5 (19) | 4 (6) | 2 (8) | 7 (10) |
VA-ECMO | 3 (3) | 2 (12) | 1 (1) | 1 (4) | 2 (3) | 3 (11) * | 0 |